Teva Pharmaceutical Industries Limited (TEVA) : The total negative money flow of $10.38 million on Friday indicates selling on strength. The inflow of money on upticks was $64.2 million, compared to $74.58 million outflow on downticks, which confirms distribution in the stock. The up to down ratio was 0.86. The negative money flow of $14.83 million in block trades reveals that the informed traders sold the stock on every bit of price strength. The traded value of the stock on uptick was $0.61 million in a block trade.The transaction value of block trade on downtick was $15.44 million. The uptick to downtick ratio was 0.04. The price action in the Teva Pharmaceutical Industries Limited (TEVA) stock suggests that both the bulls and the bears were in equilibrium. The stock traded at $50.9 with a gain of $0.51 , a change of 1.01% over the previous days close. The stock registered -1.26% for the week.
The company Insiders own 7.1% of Teva Pharmaceutical Industries Limited shares according to the proxy statements. Institutional Investors own 63.3% of Teva Pharmaceutical Industries Limited shares.
Teva Pharmaceutical Industries Limited (NYSE:TEVA): The stock opened at $51.94 and touched an intraday high of $51.94 on Friday. During the day, the stock corrected to an intraday low of $50.68, however, the bulls stepped in and pushed the price higher to close in the green at $51.22 with a gain of 0.63% for the day. The total traded volume for the day was 5,682,168. The stock had closed at $50.9 in the previous trading session.
Teva Pharmaceutical Industries Limited (TEVA) : During the past 4 weeks, traders have been relatively bearish on Teva Pharmaceutical Industries Limited (TEVA), hence the stock is down -5.39% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -1.14% relative to the S&P 500. The 4-week change in the price of the stock is -5.52% and the stock has fallen -0.64% in the past 1 week.
Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical and drug company. The Companys generic products cover almost every major therapeutic area. The Company operates its business in two segments: Generic medicines, which manufactures and sells generic pharmaceutical products in several dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams, and Specialty medicines, which delivers solutions to patients and providers via medicines, devices and services. Its Central Nervous System (CNS) portfolio includes Copaxone, Azilect and Nuvigil. Its main respiratory medicines include ProAir hydrofluoroalkane, QVAR and Duoresp Spiromax. Its oncology portfolio includes Treanda, Trisenox, Granix Synribo, Lonquex, Tevagrastim/Ratiograstim, Myocet, Trisenox and Eporatio. Its womens health portfolio includes ParaGard, Plan B One-Step OTC/Rx (levonorgestrel) and Zoely.